Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 1:227:109025.
doi: 10.1016/j.drugalcdep.2021.109025. Epub 2021 Sep 1.

Effect of HIV, antiretrovirals, and genetics on methadone pharmacokinetics: Results from the methadone antiretroviral pharmacokinetics study

Gavin Bart  1 , Le Minh Giang  2 , Hoang Yen  3 , James S Hodges  4 , Richard C Brundage  5
Affiliations

Effect of HIV, antiretrovirals, and genetics on methadone pharmacokinetics: Results from the methadone antiretroviral pharmacokinetics study

Gavin Bart et al. Drug Alcohol Depend. .

Abstract

Background: Methadone treatment of opioid use disorder in HIV-infected individuals is complicated by drug-drug interactions. Genetic and other cofactors further contribute to interindividual variability in methadone pharmacokinetics. We used population pharmacokinetics to estimate the effect of drug-drug interactions, genetics, and other cofactors on methadone pharmacokinetics in a methadone maintained population in Vietnam.

Methods: Plasma R- and S-methadone levels were measured in 309 methadone maintained individuals just before and 2-5 h following methadone dosing. A linear one-compartment population pharmacokinetic model with first-order conditional estimation with interaction was used to evaluate methadone clearance (CL/F) and volume of distribution (V/F). The influence of covariates on parameter estimates was evaluated using stepwise covariate modeling. Covariates included HIV status, antiretroviral use (efavirenz or nevirapine), weight, BMI, age, methadone dose, and 8 single nucleotide polymorphisms in across the CYP2B6, ABCB1, and NR1I3 genes.

Results: Taking either efavirenz or nevirapine increased R-methadone CL/F 220%. Nevirapine and efavirenz increased S-methadone CL/F by 404% and 273%, respectively. Variants in NR1I3 increased R- and S-methadone CL/F by approximately 20% only in patients taking efavirenz. Different alleles in ABCB1 rs2032582 either increased or decreased R-methadone CL/F by 10%. The CYP 2B6*4 variant decreased S-methadone CL/F by 18%. HIV-infection increased R- and S-methadone CL/F and V/F by 24%-39%.

Conclusions: The HIV antiretrovirals nevirapine and efavirenz significantly increase methadone clearance. Variants inNR1I3 increased the effect of efavirenz on methadone clearance. Other variants affecting methadone CL/F were also confirmed. To our knowledge, this is the first report of HIV itself affecting methadone pharmacokinetics.

Keywords: Drug-drug interactions; Genetics; HIV; Methadone; Pharmacokinetics.

PubMed Disclaimer

References

    1. Ahmad T, Valentovic MA, Rankin GO, 2018. Effects of cytochrome P450 single nucleotide polymorphisms on methadone metabolism and pharmacodynamics. Biochem. Pharmacol. 153, 196–204. - PMC - PubMed
    1. Altice FL, Friedland GH, Cooney EL, 1999. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS 13 (8), 957–962. - PubMed
    1. Bart G, Lenz S, Straka RJ, Brundage RC, 2014. Ethnic and genetic factors in methadone pharmacokinetics: a population pharmacokinetic study. Drug Alcohol Depend. 145, 185–193. - PMC - PubMed
    1. Bruce RD, Moody DE, Altice FL, Gourevitch MN, Friedland GH, 2013. A review of pharmacological interactions between HIV or hepatitis C virus medications andopioid agonist therapy: implications and management for clinical practice. Expert Rev. Clin. Pharmacol. 6 (3), 249–269. - PMC - PubMed
    1. Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, Zwickl B, Wu AW, 2000. Self-reported adherence to antiretroviral medications among participantsin HIV clinical trials: the AACTG adherence instruments. Patient Care Committee &Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care 12 (3), 255–266. - PubMed

Publication types

MeSH terms